Xenetic Biosciences enrols first patient in Phase II trial of XBIO-101 for endometrial cancer

US-based biopharmaceutical firm Xenetic Biosciences has started patient enrolment in its Phase II clinical trial of XBIO-101 (sodium cridanimod) and progestin therapy combination to treat patients with endometrial cancer.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news